Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Roswell Park Cancer Institute Corporation Health Research Inc. currently has 1 pending office action. This matter is assigned to 1 distinct examiner, KONOPKA, CATHERINE ANNE, who is responsible for 1 pending office action. The concentration of the entire pending portfolio under 1 distinct examiner suggests a singular point of contact for current prosecution efforts.
The data indicates 0 distinct art units associated with these filings. This figure may impact how the 1 pending office action is processed within the patent office's internal structure. Because KONOPKA, CATHERINE ANNE manages the only 1 pending action, the success of the current portfolio rests entirely on the resolution of this examiner's requirements. Practitioners should note that the presence of 0 distinct art units requires careful monitoring of the case's administrative status.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688261 | EXPLOITING IL33 SECRETION AS A THERAPEUTIC TARGET IN CANCER | KONOPKA, CATHERINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688261 | EXPLOITING IL33 SECRETION AS A THERAPEUTIC TARGET IN CANCER | KONOPKA, CATHERINE ANNE | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688261 | EXPLOITING IL33 SECRETION AS A THERAPEUTIC TARGET IN CANCER | KONOPKA, CATHERINE ANNE | — | §103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRoswell Park Cancer Institute Corporation Health Research Inc. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Catherine Anne Konopka has the most, with 1 of Roswell Park Cancer Institute Corporation Health Research Inc.'s pending office actions.